Cost may be an important factor in which version of oral PrEP you decide to take, especially if your healthcare system or insurance does not reimburse for the medication. The patent for branded ...

Apretude, Descovy, Truvada, and a generic version of Truvada—often referred to as PrEP—are approved for men at high risk of acquiring HIV. By Lisa L. Gill Updated by Justin Krajeski About ...

The Scottish Medicines Consortium has approved the use of Gilead’s Truvada for use in preventing new HIV infections, so called pre-exposure prophylaxis (PrEP). The decision has been hailed as a ...

Gilead Sciences has filed Descovy, its successor to HIV pre-exposure prophylaxis (PrEP) therapy Truvada, in the US, spending a priority review voucher (PRV) to set up a verdict within six months.

Two oral PrEP medications have been approved by the U.S. Food and Drug Administration (FDA)—Truvada and Descovy—and one injection drug called Apretude that must be taken once every two months.

Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and Descovy for pre-exposure prophylaxis (PrEP). The government was ...

In this month’s issue, the Sexpert advises readers on how to navigate discussions of PrEP and sexual health while in the ...

Truvada for PrEP, the name-brand version of the pill form of HIV prevention medication, was approved by the Food and Drug Administration in July 2012 for sexually active adults after having been ...

Gilead has maintained that it fully compensated the CDC for its contributions to the development of Truvada for PrEP while the government had argued that Gilead did not properly acknowledge or ...

At issue was a battle over patents for Truvada and a newer, upgraded version called Descovy — two highly effective and lucrative medications — as well as the role played by the federal ...

People who use PrEP must commit to taking the drug every day and seeing their health care provider for follow-up every three (3) months. If you are interested in discussing if a prescription for the ...

Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware federal court.